Brain glycogen decreases with increased periods of wakefulness: implications for homeostatic drive to sleep.

J Neurosci

Department of Pharmacology, Division of Neurovirology, St. Boniface Hospital Research Centre, University of Manitoba Faculty of Medicine, Winnipeg, Manitoba, R2H 2A6, Canada.

Published: July 2002

Sleep is thought to be restorative in function, but what is restored during sleep is unclear. Here we tested the hypothesis that increased periods of wakefulness will result in decreased levels of glycogen, the principal energy store in brain, and with recovery sleep levels of glycogen will be replenished, thus representing a homeostatic component of sleep drive. Using a high-energy focused microwave irradiation method to kill animals and thereby snap-inactivate glycogen-producing and -metabolizing enzymes, we determined, with accuracy and precision, levels of brain glycogen and showed these levels to decrease significantly by approximately 40% in brains of rats deprived of sleep for 12 or 24 hr. Recovery sleep of 15 hr duration after 12 hr of sleep deprivation reversed the decreases in glycogen. Using a novel histochemical method to stain brain glycogen, we found glycogen to be concentrated in white matter; this finding was confirmed biochemically in white matter dissected from rats killed with microwave irradiation. Levels of glycogen, as determined histochemically, were significantly decreased in gray and white matter with sleep deprivation, and these decreases were reversed with recovery sleep. The observed decreases in levels of brain glycogen may be a consequence of increased wakefulness and/or a component integral to the homeostatic drive to sleep.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758203PMC
http://dx.doi.org/10.1523/JNEUROSCI.22-13-05581.2002DOI Listing

Publication Analysis

Top Keywords

brain glycogen
16
levels glycogen
12
recovery sleep
12
white matter
12
sleep
11
increased periods
8
periods wakefulness
8
homeostatic drive
8
drive sleep
8
glycogen
8

Similar Publications

Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer's disease (AD) and related tauopathies. In the last decade, tau hyper-phosphorylation has gained considerable concern in AD therapeutic development. Tauopathies are manifested with a broad spectrum of symptoms, from dementia to cognitive decline and motor impairments.

View Article and Find Full Text PDF

Pharmacological modulation of Sigma-1 receptor ameliorates pathological neuroinflammation in rats with diabetic neuropathic pain via the AKT/GSK-3β/NF-κB pathway.

Brain Res Bull

January 2025

Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang, 712046, PR China; Key Laboratory of Pharmacodynamic Mechanism and Material Basis of Traditional Chinese Medicine, Shaanxi Administration of Traditional Chinese Medicine, Xianyang 712046, PR China. Electronic address:

Diabetic neuropathic pain (DNP) is a common complication of diabetes mellitus (DM) and is characterized by spontaneous pain and neuroinflammation. The Sigma-1 receptor (Sig-1R) has been proposed as a target for analgesic development. It is an important receptor with anti-inflammatory properties and has been found to regulate DNP.

View Article and Find Full Text PDF

Homozygous missense variant in causes early-onset neurodegeneration, leukoencephalopathy and autoinflammation.

J Med Genet

January 2025

Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

Biallelic pathogenic variants in cause a fatal autosomal recessive multisystem disorder characterized by recurrent autoinflammation, hypomyelination, progressive neurodegeneration, microcephaly, failure to thrive, liver dysfunction, respiratory chain defects and accumulation of glycogen in skeletal muscle. No missense variants in have been reported to date.We report a 6-year-old boy with microcephaly, global developmental delays, lower limb spasticity with hyperreflexia, epilepsy, abnormal brain MRI, failure to thrive, recurrent fevers and transaminitis.

View Article and Find Full Text PDF

Methionine sulfoximine (MSO) is a compound originally discovered as a byproduct of agene-based milled flour maturation. MSO irreversibly inhibits the astrocytic enzyme glutamine synthase (GS) but also interferes with the transport of glutamine (Gln) and of glutamate (Glu), and γ-aminobutyric acid (GABA) synthesized within the Glu/Gln-GABA cycle, in this way dysregulating neurotransmission balance in favor of excitation. No wonder that intraperitoneal administration of MSO has long been known to induce behavioral and/or electrographic seizures.

View Article and Find Full Text PDF

Disruption of gut microbiota balance is known to contribute to the development of anxiety; however, it remains unclear whether dysbiosis-induced anxiety involves the glycogen synthase kinase-3β (GSK-3β)/cAMP response element binding protein (CREB)/brain-derived neurotrophic factor (BDNF) pathway and neurogenesis in the ventral hippocampal dentate gyrus (DG). In this study, Male ddY mice were administered an antibacterial cocktail to induce dysbiosis. The dysbiosis model displayed anxiety-like behaviors in the hole-board and elevated plus-maze tests, decreased the phosphorylation levels of GSK-3β (Ser9) and CREB, decreased the expression level of BDNF in the ventral hippocampus, and reduced neurogenesis in the ventral hippocampal DG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!